The trial was conducted in patients with advanced NSCLC with KRAS G12C mutations, who had progressed after previous platinum-based chemotherapy and PD-1 or PD-L1 inhibitor treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.